Clinical trials: Hepatobiliary Diseases
NAFLD, NASH - Nonalcoholic Steatohepatitis
The Franciscus Obesity NASH Study
The purpose of this study is to evaluate Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) changes in terms of steatosis and elasticity in patients with morbid obesity 1, 3 and 5 years after…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Obesity, Morbid
- Trial name
- FONS (NCT05499949)
- Testing
- NASH screening, Cardiac dysfunction screening, Liver biopsy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Franciscus Gasthuis
Diabetes Mellitus Type 2
Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes
Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by an abnormal accumulation of fat not due to alcohol or drug consumption that can evolve into steatohepatitis (NASH), fibrosis and cirrhosis.
- Trial name
- PoLiFat (NCT06895018)
- Testing
- Supplementation with Polyphenol Rich Drink
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
The primary aim of the study is to determine the impact on hepatic steatosis of replacing premeal rapid-acting insulin for exenatide (Byetta) while maintaining bedtime long-acting detemir (Levemir) insulin in well-controlled…
- Trial name
- NCT01006889
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
End Stage Liver DIsease
Adding Specialist Palliative Care to Transplantation Pilot Trial
Specialist palliative care has been shown to be beneficial for patients experiencing serious illness, but has not been studied for patients being evaluated for liver transplantation.
- Trial name
- ASPECT-Pilot (NCT05147935)
- Testing
- Palliative Care Consultation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University Medical Center
NAFLD
Effects of Tomato Products in Children With NAFLD
CONTROLLED TRIAL ON THE EFFECT OF TOMATO PRODUCTS IN OBESE CHILDREN WITH NON ALCOHOLIC FATTY LIVER DISEASE Aim of the study To evaluate the effect of the addition of a daily dose of lycopene enriched tomato sauce on the progress…
- Trial name
- NCT03463967
- Testing
- Lycopene-enriched tomato juice, Energy-restricted diet
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- Federico II University
NAFLD
Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse.
- Trial name
- NCT05930093
- Testing
- 2 cap.LivPhcD/per day, 4 cap.LivPhcD/per day, 6 cap.LivPhcD/per day
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- TCM Biotech International Corp.
NAFLD, MASLD
NAFLD Clinical Care Pathway
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer.
- Trial name
- NCCP (NCT06671886)
- Testing
- E-trigger
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Steatohepatitis, Nonalcoholic
The COherence of Scatter Identification and Exclusion Algorithm Study
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040.
- Trial name
- COSIE (NCT06975579)
- Testing
- Ultrasound image processing
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Non-Alcoholic Fatty Liver Disease
NAFLD Study: US vs Liver Biopsy
Evaluate the diagnostic accuracy of the new ultrasound software vs hepatic histology, the current reference standard for the diagnosis of NAFLD and NASH in 20 obese patients (BMI> 30) candidates for laparoscopic bariatric surgery…
- Trial name
- NAFLD (NCT04101162)
- Testing
- shear waves elastography; liver biopsy
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
NAFLD, Hiv
Lifestyle Modification Programme for HIV-infected Individuals With Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is rising in prevalence, and will likely become the predominant cause of chronic liver disease in HIV-infected individuals.
- Trial name
- NCT03913351
- Testing
- Lifestyle modification
- Where
- Hong Kong
- Volunteers
- 96 people
- Sponsor
- Chinese University of Hong Kong
NAFLD, Obesity, Adolescent
Impact of Weight Loss Surgery in Adolescents With NAFLD
This study will assess the impact of weight loss surgery (WLS) on non-alcoholic fatty liver disease (NAFLD) in adolescents as well as the interaction between NAFLD and cardiometabolic risk.
- Trial name
- AWLS (NCT02952170)
- Testing
- MRI
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
GLP-1 analogues represent new treatments in diabetes that cause weight loss. Their effect on NASH in humans is unknown. A decrease in Alanine Aminotransferase (ALT) has been reported in pooled Exenatide/Placebo and…
- Trial name
- REALIST (NCT03648554)
- Testing
- dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring
- Where
- 9 sites in France
- Volunteers
- 93 people
- Sponsor
- Central Hospital, Nancy, France
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
The Liver in the World Trade Center Health Program General Responder Cohort and Controls
This project investigates whether exposure to the World Trade Center Attack is a risk factor for liver injury.
- Trial name
- NCT03858920
- Testing
- Fibroscan of Liver, Low-dose non-contrast CT
- Where
- United States
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Liver Failure
Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure
The objective of this trial is to evaluate the impact of elimination of albumin bound substances during albumin dialysis (MARS®) on mortality and the clinical time course in patients with a recent severe clinical deterioration of…
- Trial name
- RELIEF (NCT00614146)
- Testing
- MARS device, Standard medical therapy
- Where
- 19 sites in Austria, Belgium and 7 more
- Volunteers
- 59 people
- Sponsor
- Vantive Health LLC
Coronary Disease, Non-alcoholic Fatty Liver Disease
Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease
Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, which is one of the major risk factors of coronary heart disease (CHD).
- Conditions
- Coronary Disease, Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques
- Trial name
- NILS-R-CHD (NCT02779946)
- Testing
- Fibro Scan, PNPLA3
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- University of Leipzig
Compensated Advanced Chronic Liver Disease
Impact of Metabolic Disorders on cACLD Outcomes
This multicenter, prospective, cohort study is designed to investigate how metabolic disorders (such as obesity, diabetes, and high cholesterol) influence the progression of liver disease in patients with compensated advanced…
- Trial name
- NCT07534046
- Testing
- Observational Study
- Volunteers
- 4,307 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Polycystic Ovary Syndrome (PCOS), Metabolic Dysfunction-Associated Steatotic Liver Disease
Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS)
This single-center, prospective, observational, cross-sectional mechanistic pilot study will evaluate whether polycystic ovary syndrome (PCOS) contributes to hepatic steatosis in adolescent girls independently of adiposity.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Metabolic Dysfunction-Associated Steatotic Liver Disease, Pediatric Obesity, Hyperandrogenism
- Trial name
- COMPASSpedPCOS (NCT07731373)
- Testing
- Extended Serum Biomarker and Hormonal Panel, Liver Elastography with Controlled Attenuation Parameter, Targeted Genotyping of PNPLA3 rs738409 and HSD17B13 rs72613567
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kayseri City Hospital
End Stage Liver Disease, Hepatic Encephalopathy
Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging
The purpose of this study is to determine whether hepatic encephalopathy, measured through magnetic resonance imaging, electroencephalogram and neuropsychological evaluation adds prognostic information to patients who are waiting…
- Trial name
- NCT01434056
- Where
- Brazil
- Volunteers
- 400 people
- Sponsor
- Hospital Israelita Albert Einstein
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)